S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Palatin Technologies Stock Forecast, Price & News

0.00 (0.00%)
(As of 01/21/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
2.22 million shs
Average Volume
1.80 million shs
Market Capitalization
$90.92 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PTN News and Ratings via Email

Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter.

Palatin Technologies logo

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.


Palatin Technologies Inc. Q1 Earnings Summary
November 15, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$120 thousand
Book Value
$0.22 per share


Net Income
$-33.60 million
Pretax Margin




Free Float
Market Cap
$90.92 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.81 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Palatin Technologies (NYSEAMERICAN:PTN) Frequently Asked Questions

Is Palatin Technologies a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Palatin Technologies stock.
View analyst ratings for Palatin Technologies
or view top-rated stocks.

Are investors shorting Palatin Technologies?

Palatin Technologies saw a decline in short interest during the month of December. As of December 31st, there was short interest totaling 6,850,000 shares, a decline of 40.4% from the December 15th total of 11,490,000 shares. Based on an average trading volume of 8,750,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 3.3% of the company's stock are short sold.
View Palatin Technologies' Short Interest

When is Palatin Technologies' next earnings date?

Palatin Technologies is scheduled to release its next quarterly earnings announcement on Tuesday, February 15th 2022.
View our earnings forecast for Palatin Technologies

How were Palatin Technologies' earnings last quarter?

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) posted its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.03). The biopharmaceutical company earned $0.16 million during the quarter. During the same period last year, the business posted ($0.02) earnings per share.
View Palatin Technologies' earnings history

What price target have analysts set for PTN?

2 Wall Street analysts have issued 1-year price targets for Palatin Technologies' stock. Their forecasts range from $2.00 to $5.00. On average, they expect Palatin Technologies' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 790.6% from the stock's current price.
View analysts' price targets for Palatin Technologies
or view top-rated stocks among Wall Street analysts.

Who are Palatin Technologies' key executives?

Palatin Technologies' management team includes the following people:
  • Carl Spana, President, Chief Executive Officer & Director
  • Stephen T. Wills, COO, CFO, Secretary, Treasurer & Executive VP
  • Michael B. Raizman, Chief Medical Officer
  • John Dodd, Senior Vice President-Preclinical Development
  • James E. Hattersley, Senior Vice President-Business Development

What other stocks do shareholders of Palatin Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include (XXII), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM).

What is Palatin Technologies' stock symbol?

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

How do I buy shares of Palatin Technologies?

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Palatin Technologies' stock price today?

One share of PTN stock can currently be purchased for approximately $0.39.

How much money does Palatin Technologies make?

Palatin Technologies has a market capitalization of $90.92 million and generates $120 thousand in revenue each year. The biopharmaceutical company earns $-33.60 million in net income (profit) each year or ($0.15) on an earnings per share basis.

How many employees does Palatin Technologies have?

Palatin Technologies employs 20 workers across the globe.

What is Palatin Technologies' official website?

The official website for Palatin Technologies is www.palatin.com.

Where are Palatin Technologies' headquarters?

Palatin Technologies is headquartered at 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States.

How can I contact Palatin Technologies?

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at (609) 495-2200, via email at [email protected], or via fax at 609-495-2202.

This page was last updated on 1/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.